Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
18.09.2017 12:35:00

Medical Research Stock Performance Review -- Agilent Technologies, Alere, Quintiles IMS, and Thermo Fisher Scientific

NEW YORK, September 18, 2017 /PRNewswire/ --

If you want a Stock Review on A, ALR, Q, or TMO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. As access to health care expands around the world, the need for diagnostic and research laboratory services will also increase. Growth in the industry is impacted by aging populations and rising demand for preventive care and personalized medical treatments. This morning, DailyStockTracker.com takes a closer look at select equities in the Medical Laboratories and Research space to see how they have fared over the previous trading sessions: Agilent Technologies Inc. (NYSE: A), Alere Inc. (NYSE: ALR), Quintiles IMS Holdings Inc. (NYSE: Q), and Thermo Fisher Scientific Inc. (NYSE: TMO). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:

http://dailystocktracker.com/register/

Agilent Technologies 

California headquartered Agilent Technologies Inc.'s shares rose 0.43%, finishing last Friday's session at $65.96. A total volume of 2.27 million shares was traded, which was above their three months average volume of 1.73 million shares. Over the last month and the previous three months, the stock has advanced 6.15% and 10.84%, respectively. Furthermore, the Company's shares have gained 44.78% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.80% and 20.24%, respectively. Additionally, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 68.15.

On September 13th, 2017, Agilent Technologies announced that it has obtained 510(k) clearance from the US FDA for the GenetiSure Dx Postnatal Assay, the Company's first comparative genomic hybridization assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital irregularities, and unexplained dysmorphic features earlier and more accurately than traditional methods. Your complete research report on A can be retrieved for free at:

http://dailystocktracker.com/registration/?symbol=A

Alere 

On Friday, shares in Massachusetts headquartered Alere Inc. ended the session 0.70% lower at $49.76. The stock recorded a trading volume of 1.28 million shares. The Company's shares have gained 0.28% in the last month and 27.69% on an YTD basis. The stock is trading above its 200-day moving average by 11.27%. Moreover, shares of Alere, which provides diagnostic tests for infectious disease, cardiometabolic disease, and toxicology in the US, Europe, and internationally, have an RSI of 50.50. A free report on ALR is just a click away at:

http://dailystocktracker.com/registration/?symbol=ALR

Quintiles IMS Holdings 

North Carolina headquartered Quintiles IMS Holdings Inc.'s stock declined 1.03%, to close the day at $94.47. A total volume of 5.76 million shares was traded, which was above their three months average volume of 1.79 million shares. The Company's shares have advanced 2.03% in the last one month, 8.42% over the previous three months, and 24.22% since the start of this year. The stock is trading 2.27% and 12.97% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Quintiles IMS have an RSI of 48.60.

On September 15th, 2017, Quintiles IMS announced the pricing of an underwritten, secondary public offering of 9,000,000 shares of the Company's common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Leonard Green & Partners, L.P. at a price to the public of $95.25 per share. The Company intends to repurchase from the underwriter 4,000,000 shares. Sign up for your complimentary research report on Q at:

http://dailystocktracker.com/registration/?symbol=Q

Thermo Fisher Scientific 

Shares in Massachusetts headquartered Thermo Fisher Scientific Inc. recorded a trading volume of 3.27 million shares, which was above their three months average volume of 1.43 million shares. The stock ended at $190.63, slightly down 0.55% from the last trading session. The Company's shares have gained 8.66% in the past month, 9.02% over the previous three months, and 35.10% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.10% and 16.72%, respectively. Furthermore, shares of the Company have an RSI of 65.76.

On September 06th, 2017, research firm Morgan Stanley resumed its 'Overweight' rating on the Company's stock, with a target price of $220 per share.

On September 13th, 2017, Thermo Fisher Scientific announced the expiration of the subsequent offering period of its previously announced tender offer to purchase all of the outstanding ordinary shares of Patheon N.V. The Company completed the acquisition of Patheon on August 29th, 2017. The subsequent offering period expired at 12:01 a.m. New York City Time on that day. Register for free on DailyStockTracker.com and download the latest research report on TMO at:

http://dailystocktracker.com/registration/?symbol=TMO

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com

Analysen zu Thermo Fisher Scientific Incmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Agilent Technologies Inc. 130,84 3,53% Agilent Technologies Inc.
Thermo Fisher Scientific Inc 496,00 1,77% Thermo Fisher Scientific Inc